The most recent version of NG28, the National Institute for Health and Care Excellence's (NICE) guidelines for managing type 2 diabetes in adults, has been released on February 18, 2026.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prescriptions for GLP-1 receptor agonists and SGLT2 ...

Patients with type 2 diabetes who received sodium-glucose cotransporter-2 inhibitors demonstrated a nearly 50% lower risk for systemic autoimmune rheumatic disease vs. those who received dipeptidyl ...

Two classes of diabetes drugs may also improve cardiovascular and kidney disease outcomes in people with or without diabetes. In a meta-analysis involving more than 70,000 patients with diabetes, ...

New findings add to the pile of research on the possible neuroprotective effects of drugs like dapagliflozin, empagliflozin, and dulaglutide for patients with type 2 diabetes. The primary outcome was ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

ABU DHABI, United Arab Emirates — Whether a newer class of drugs, the sodium glucose cotransporter 2 (SGLT2) inhibitors, should now be considered as first-line therapy in patients with type 2 diabetes ...

Patients with type 2 diabetes (T2D) who initiated SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection (UTI) had lower risks for mortality, kidney complications, and ...

SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. Sex ...

STOCKHOLM -- The sodium glucose co-transporter 2 (SGLT2) class of diabetes medications may offer more protection against diabetic retinopathy as compared with other hypoglycemic agents, an analysis of ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ. The authors ...